论文部分内容阅读
目的:评价艾易舒注射液对乳腺癌术后患者化疗后细胞免疫功能及毒副反应影响。方法:将70例Ⅰ~ⅢA期乳腺癌患者随机分为艾易舒加化疗组(36例)和单纯化疗组(34例),检测治疗前后T淋巴细胞亚群及NK细胞活性,比较两组的毒副反应及生活质量改变。结果:艾易舒加化疗组患者CD3、CD4、CD8水平和CD4/CD8比值及NK细胞活性高于单纯化疗组(P<0.05);艾易舒加化疗组患者白细胞减少程度明显小于单纯化疗组(χ2=7.44,P=0.006),其他毒副反应差异无显著性(P>0.05);艾易舒加化疗组36.11%(13/36)患者KPS提高幅度高于单纯化疗组(11.76%,4/34)(χ2=5.64,P=0.018);艾易舒加化疗组44.44%患者体重增加,高于单纯化疗组(17.65%)(χ2=6.66,P=0.036)。结论:艾易舒注射液可作为乳腺癌患者术后化疗的辅助用药,提高免疫能力,减轻化疗的毒副反应,提高患者的生活质量。
Objective: To evaluate the effect of Ai Yi Shu injection on cellular immune function and toxicity after postoperative chemotherapy in patients with breast cancer. Methods: A total of 70 patients with stage Ⅰ ~ ⅢA breast cancer were randomly divided into two groups: 36 patients in the group treated with Yi-Yi Su-Jia and 36 patients in the chemotherapy alone group. T-lymphocyte subsets and NK cell activity were measured before and after treatment. Toxicity and quality of life changes. Results: The levels of CD3, CD4, CD8 and CD4 / CD8 and the activity of NK cells in patients with Yi-Yi-Su-Jia chemotherapy group were higher than those in the chemotherapy alone group (P <0.05). The leucopenia in patients with Yi-Yi- (χ2 = 7.44, P = 0.006). There was no significant difference in other toxicities (P> 0.05). The KPS increase rate in 36.11% (13/36) 4/34) (χ2 = 5.64, P = 0.018). The body weight of 44.44% patients in the Yi-Yi-Shu-Jia chemotherapy group was higher than that in the chemotherapy-only group (χ2 = 6.66, P = 0.036). Conclusion: Yi Yi Shu injection can be used as adjuvant chemotherapy in patients with breast cancer after surgery to improve immune capacity, reduce the side effects of chemotherapy and improve patient quality of life.